BridgeMD
An open label, multi-center, Phase IV rollover protocol to evaluate long term safety data
EU CTIS ID: 2024-515283-31-00
What this study is testing
To evaluate long term safety data, i.e. SAEs and AEs
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patient is currently enrolled in a Novartis-sponsored GDD or GMA study or Incyte-sponsored study (where Incyte can delegate the sponsorship to a preferred CRO, if applicable) and are receiving either ruxolitinib or combination of ruxolitinib and panobinostat, or combinations of ruxolitinib and siremadlin, or ruxolitinib and rineterkib and fulfilled all the requirements of the parent protocol. Please refer to the list of parent studies in Appendix 2.
- Patient is currently benefitting from the treatment with ruxolitinib monotherapy or combination of ruxolitinib and panobinostat, or combinations of ruxolitinib and siremadlin or ruxolitinib and rineterkib as determined by the investigator.
You likely can't join if
- Patient has been permanently discontinued from study treatment in parent study due to any reason.
- Patient’s indication is currently approved and reimbursed in the corresponding country for ruxolitinib monotherapy or combination of ruxolitinib with panobinostat, or ruxolitinib and siremadlin or ruxolitinib and rineterkib (if the patient is receiving combination treatment in the parent study).
The study team makes the final eligibility decision.
Where it's taking place
- India
- Turkey
- Thailand
- Chile
- Argentina
- Saudi Arabia
- Taiwan
- Jordan
- Korea, Republic of
- Japan
- Lebanon
- Canada
- Australia
- South Africa
- Mexico
- China
- Brazil
- Russian Federation
- Israel
- Switzerland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 0-17 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include India; Turkey; Thailand; Chile; Argentina; Saudi Arabia and 14 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.